Chiesi Farmaceutici S.p.A.
PharmaParma, Italy, Italy · Est. 1935 · 6,000 employees
Chiesi Farmaceutici is an Italian pharmaceutical company specializing in respiratory diseases, rare diseases, and primary care therapies.
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
4
Indications↗
Distinct diseases across all programs
175
Clinical Trials↗
All sponsored trials (all statuses)
19
Orange Book Patents
Across 4 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Phase 33
Phase 22
By Therapeutic Area
top 3
Rare Disease
240%
Respiratory
240%
Dermatology
120%
R&D Momentum
60/100
Pipeline Velocity
27/100
Trial Completion Rate
87/100
Pipeline Concentration
36/100
Pipeline Freshness
80/100
Strategic Signals
- ↗Active in Dermatology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 18, 2026
Recruiting
A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF6467 After Single and Repeated Ascending Doses by Intranasal Route in Healthy Adult Subjects
Sep 18, 2026
Recruiting
A Phase IIb, Multicentre, Randomised, Double Blind, Placebo Controlled, Three-arm Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability at Week 24 of 2 Doses of CHF10067 (Zampilimab),in Participants With Idiopathic Pulmonary Fibrosis
Sep 11, 2026
Completed
AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS); Multinational, Multicentre, Non-pharmacological Intervention, Cross-sectional and Longitudinal Study.
Sep 11, 2026
Completed
A 12-week Double-blind, Multicentre, Randomised, Active-controlled, 2-arm, Parallel-group Clinical Trial to Evaluate the Safety of CHF5993 pMDI 200/6/12.5 μg HFA-152a, Compared to CHF5993 pMDI 200/6/12.5 μg HFA-134a, in Subjects With Asthma.
Sep 11, 2026
Completed
Multicentre Observational, Prospective Cohort Study Including Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Who Receive Cangrelor i.v. Transitioning to Clopidogrel, Prasugrel or Ticagrelor Per os
Earlier
Aug 11, 2026TrialMulti-centre, Open-label Trial to Assess the saFety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigaLsidase Alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed FabrY Disease
Aug 11, 2026TrialA 12-week, Multicentre, Multinational, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus Seretide® 500/50 (Fluticasone 500 µg Plus Salmeterol 50 µg/Actuation), 1 Inhalation b.i.d., in Patients With Chronic Obstructive Pulmonary Disease
Aug 11, 2026TrialA 12-week, Multicenter, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6mg NEXThaler, 2 Inhalations b.i.d, Versus Foster 100/6mg pMDI, 2 Puffs b.i.d in Patients With Controlled Asthma.
4 more events
Aug 5, 2026TrialAn Open-label, Fixed-sequence, Non-randomized, Drug-drug Interaction Study to Evaluate the Effect of CHF10196 on the Pharmacokinetics of Dabigatran (P-gp Substrate) and Rosuvastatin (BCRP Substrate) in Healthy Male Participants.
Aug 1, 2026TrialA Pragmatic, Phase IV, Randomized, Open-label, Multinational, Multicentre, 2-arm Parallel Group, Prospective Study Comparing Efficacy and Safety of Single Inhaler ICS/LABA/LAMA (Beclometasone/Formoterol Fumarate/Glycopyrronium Bromide [87/5/9 pMDI { BD/FF/GB -100/6/12.5 μg} ]) vs Single Inhaler ICS/LABA (Beclometasone Dipropionate Plus Formoterol Fumarate [200/6 pMDI { BD/FF - 200/6 μg} ]) in Asthma Subjects
Jul 21, 2026TrialA Phase 3 Randomised Double Blind Randomised Parallel Multinational Trial Comparing a Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate to Foster® in Patients With Chronic Obstructive Pulmonary Disease
Jul 21, 2026TrialA 24-week, Double Blind, Double Dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group,Active Controlled Clinical Trial of Fixed Combination of Beclometasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide Administered Via pMDI (CHF 5993) Versus the Fixed Combination of Budesonide Plus Formoterol Fumarate (Symbicort® Turbuhaler®) in Patients With Chronic Obstructive Pulmonary Disease
Details
Company Info
Company Overview
—
Mkt Cap
$2.3B
Revenue
—
Cash
CEOStefano Gobbato
Founded1935
Employees6,000
HQParma, Italy, Italy
Websitechiesi.com
LinkedInCompany Page
Therapeutic Focus
RespiratoryRare DiseasesSpecialty CarePrimary Care
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Dermatology
Rare Disease
Dermatology
Rare Disease
Fabry Disease
PRX-102 /kgPhase 3
ELFABRIOPhase 3
Respiratory
Bronchiectasis
CHF6333Phase 2
Regulatory
Regulatory Timeline
20182 events
FDAOct 5
REVCOVI — REVCOVI
Application BLA761092 (BLA)
FDAApr 20
Ferriprox — FERRIPROX
Application NDA208030 (NDA)
20193 events
FDAOct 23
Kengreal — KENGREAL
Application NDA204958
FDAJul 25
Ferriprox — FERRIPROX
Application NDA021825 (NDA)
FDAJul 25
Ferriprox — FERRIPROX
Application NDA021825
20203 events
FDAMay 19
Ferriprox — FERRIPROX
Application NDA212269 (NDA)
FDAFeb 20
Ferriprox — FERRIPROX
Application NDA208030
FDAFeb 20
Ferriprox — FERRIPROX
Application NDA021825
20216 events
FDANov 30
Ferriprox — FERRIPROX
Application NDA212269
FDANov 30
Ferriprox — FERRIPROX
Application NDA208030
FDANov 30
Ferriprox — FERRIPROX
Application NDA021825
FDAApr 30
Ferriprox — FERRIPROX
Application NDA212269
FDAApr 30
Ferriprox — FERRIPROX
Application NDA208030
FDAApr 30
Ferriprox — FERRIPROX
Application NDA021825
20232 events
FDAMay 9
ELFABRIO — ELFABRIO
Application BLA761161 (BLA)
FDAJan 26
Kengreal — KENGREAL
Application NDA204958
20253 events
FDAMar 26
Ferriprox — FERRIPROX
Application NDA021825
FDAMar 26
Ferriprox — FERRIPROX
Application NDA212269
FDAMar 26
Ferriprox — FERRIPROX
Application NDA208030
20261 event
FDAFeb 25
Juxtapid — JUXTAPID
Application NDA203858 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)